CN113905736A - 用于治疗孤独症谱系障碍的选择性组胺h3受体拮抗剂 - Google Patents

用于治疗孤独症谱系障碍的选择性组胺h3受体拮抗剂 Download PDF

Info

Publication number
CN113905736A
CN113905736A CN202080040238.0A CN202080040238A CN113905736A CN 113905736 A CN113905736 A CN 113905736A CN 202080040238 A CN202080040238 A CN 202080040238A CN 113905736 A CN113905736 A CN 113905736A
Authority
CN
China
Prior art keywords
asd
treatment
compound
pharmaceutically acceptable
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080040238.0A
Other languages
English (en)
Chinese (zh)
Inventor
V·罗曼
G·I·勒韦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CN113905736A publication Critical patent/CN113905736A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074—Filling capsules; Related operations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080040238.0A 2019-05-31 2020-05-29 用于治疗孤独症谱系障碍的选择性组胺h3受体拮抗剂 Pending CN113905736A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1900190 2019-05-31
HUP1900190A HU231525B1 (hu) 2019-05-31 2019-05-31 Szelektív hisztamin H3 receptor antagonisták autizmus spektrum betegség kezelésére
PCT/IB2020/055104 WO2020240489A1 (en) 2019-05-31 2020-05-29 Selective histamine h3 receptor antagonists for treating autism spectrum disorder

Publications (1)

Publication Number Publication Date
CN113905736A true CN113905736A (zh) 2022-01-07

Family

ID=89992916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080040238.0A Pending CN113905736A (zh) 2019-05-31 2020-05-29 用于治疗孤独症谱系障碍的选择性组胺h3受体拮抗剂

Country Status (8)

Country Link
US (1) US20220235034A1 (https=)
EP (1) EP3976035A1 (https=)
JP (1) JP2022534973A (https=)
CN (1) CN113905736A (https=)
CA (1) CA3141694A1 (https=)
EA (1) EA202193155A1 (https=)
HU (1) HU231525B1 (https=)
WO (1) WO2020240489A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012190A2 (en) * 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
CN105452222A (zh) * 2013-03-06 2016-03-30 吉瑞工厂 包含苯氧基哌啶核结构的h3拮抗剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012190A2 (en) * 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
CN105452222A (zh) * 2013-03-06 2016-03-30 吉瑞工厂 包含苯氧基哌啶核结构的h3拮抗剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIEGO BARONIO等: "Effects of an H3R Antagonist on the Animal Model of Autism Induced by Prenatal Exposure to Valproic Acid", 《PLOS ONE》, pages 1 - 11 *
NERMIN EISSA等: "The histamine H3R antagonist DL77 attenuates autistic behaviors in a prenatal valproic acid-induced mouse model of autism", 《SCIENTIFIC REPORTS》, vol. 8, pages 1 - 15 *
徐祥清等: "孤独症谱系障碍的药物治疗研究进展", 《药学学报》, vol. 53, no. 3, pages 321 - 327 *

Also Published As

Publication number Publication date
HU231525B1 (hu) 2024-08-28
US20220235034A1 (en) 2022-07-28
EA202193155A1 (ru) 2022-03-22
CA3141694A1 (en) 2020-12-03
JP2022534973A (ja) 2022-08-04
WO2020240489A1 (en) 2020-12-03
EP3976035A1 (en) 2022-04-06
HUP1900190A1 (hu) 2020-12-28

Similar Documents

Publication Publication Date Title
ES2678794T3 (es) Terapia para trastornos neurológicos basada en baclofeno y acamprosato
CA3079259A1 (en) Ganaxolone for use in treating genetic epileptic disorders
CN108420819A (zh) 用于治疗神经障碍的新组合物
JP2007513169A (ja) 自殺傾向を予防しまたは減少させるための、および自殺傾向に関連する大うつ病を治療するためのメマンチン
JP2025143406A (ja) 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
CA2734859A1 (en) Methods for treating cns disorders
CN105764510A (zh) H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途
US20230181572A1 (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2022113008A1 (en) Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
CN113905736A (zh) 用于治疗孤独症谱系障碍的选择性组胺h3受体拮抗剂
EA046455B1 (ru) Селективные антагонисты h3-гистаминовых рецепторов для лечения расстройства аутистического спектра
WO2022107146A1 (en) Use of pridopidine and analogs for treating rett syndrome
HK40067131A (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HK40067131B (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
EA048505B1 (ru) Производные карбамоилциклогексана для лечения расстройства аутистического спектра
OA20885A (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder.
WO2002051416A1 (fr) Medicaments ameliorant les comportements de la vie courante chez des personnes atteintes de la maladie d'alzheimer
CN114761008A (zh) 用于在患有痴呆的患者中治疗行为和心理症状的方法
BR112020013697A2 (pt) compostos para tratamento de sintomas negativos e comprometimentos cognitivos
BR122023014589B1 (pt) Usos de formulação farmacêutica que compreende di-hidrato de monocloridrato de 2-((1-(2-(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil) isoindolin-1-ona

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination